Dr. Haseena Cassim

Haseena Cassim is a clinical researcher specializing in paediatric and maternal HIV, with a strong focus on antiretroviral therapy optimization across the life course. Her work is closely linked to major international trial networks, including IMPAACT and ODYSSEY, contributing to evidence that informs global HIV treatment guidelines for pregnant women, infants, children, and adolescents.

Her publications center on the safety, pharmacokinetics, and efficacy of dolutegravir-based regimens, exploring virological suppression, resistance patterns, neuropsychiatric outcomes, and drug–drug interactions. She has also examined bone, renal, and folate-related outcomes in pregnancy and infancy, advancing understanding of maternal–child safety in contemporary HIV care.

Cassim’s research is distinguished by rigorous analyses of randomized trial data and a translational approach that bridges pharmacology and clinical outcomes. Her contributions support safer, more effective, and child-friendly treatment strategies, particularly in resource-limited settings where the burden of paediatric HIV remains high.